vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and VICOR CORP (VICR). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $113.0M, roughly 1.6× VICOR CORP). VICOR CORP runs the higher net margin — 18.3% vs 1.6%, a 16.6% gap on every dollar of revenue. On growth, VICOR CORP posted the faster year-over-year revenue change (20.2% vs 5.0%). Over the past eight quarters, VICOR CORP's revenue compounded faster (14.7% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Vicor Corporation is a manufacturer of power modules headquartered in Andover, Massachusetts.
PCRX vs VICR — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $113.0M |
| Net Profit | $2.9M | $20.7M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | 59.7% |
| Net Margin | 1.6% | 18.3% |
| Revenue YoY | 5.0% | 20.2% |
| Net Profit YoY | — | 713.9% |
| EPS (diluted) | $0.07 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $113.0M | ||
| Q4 25 | $196.9M | $107.3M | ||
| Q3 25 | $179.5M | $110.4M | ||
| Q2 25 | $181.1M | $96.0M | ||
| Q1 25 | $168.9M | $94.0M | ||
| Q4 24 | $187.3M | $96.2M | ||
| Q3 24 | $168.6M | $93.2M | ||
| Q2 24 | $178.0M | $85.9M |
| Q1 26 | $2.9M | $20.7M | ||
| Q4 25 | — | $46.5M | ||
| Q3 25 | $5.4M | $28.3M | ||
| Q2 25 | $-4.8M | $41.2M | ||
| Q1 25 | $4.8M | $2.5M | ||
| Q4 24 | — | $10.2M | ||
| Q3 24 | $-143.5M | $11.6M | ||
| Q2 24 | $18.9M | $-1.2M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 55.4% | ||
| Q3 25 | 80.9% | 57.5% | ||
| Q2 25 | 77.4% | 95.9% | ||
| Q1 25 | 79.7% | 47.2% | ||
| Q4 24 | 78.7% | 52.4% | ||
| Q3 24 | 76.9% | 49.1% | ||
| Q2 24 | 75.1% | 49.8% |
| Q1 26 | 3.9% | 59.7% | ||
| Q4 25 | 1.2% | 14.6% | ||
| Q3 25 | 3.5% | 18.9% | ||
| Q2 25 | 4.7% | 47.3% | ||
| Q1 25 | 1.2% | -0.2% | ||
| Q4 24 | 13.2% | 9.6% | ||
| Q3 24 | -82.8% | 5.8% | ||
| Q2 24 | 15.9% | 0.2% |
| Q1 26 | 1.6% | 18.3% | ||
| Q4 25 | — | 43.4% | ||
| Q3 25 | 3.0% | 25.6% | ||
| Q2 25 | -2.7% | 42.9% | ||
| Q1 25 | 2.8% | 2.7% | ||
| Q4 24 | — | 10.7% | ||
| Q3 24 | -85.1% | 12.4% | ||
| Q2 24 | 10.6% | -1.4% |
| Q1 26 | $0.07 | $0.44 | ||
| Q4 25 | $0.05 | $1.01 | ||
| Q3 25 | $0.12 | $0.63 | ||
| Q2 25 | $-0.11 | $0.91 | ||
| Q1 25 | $0.10 | $0.06 | ||
| Q4 24 | $0.38 | $0.24 | ||
| Q3 24 | $-3.11 | $0.26 | ||
| Q2 24 | $0.39 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $404.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $754.1M |
| Total Assets | $1.2B | $804.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $404.2M | ||
| Q4 25 | $238.4M | $402.8M | ||
| Q3 25 | $246.3M | $362.4M | ||
| Q2 25 | $445.9M | $338.5M | ||
| Q1 25 | $493.6M | $296.1M | ||
| Q4 24 | $484.6M | $277.3M | ||
| Q3 24 | $453.8M | $267.6M | ||
| Q2 24 | $404.2M | $251.9M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | $754.1M | ||
| Q4 25 | $693.1M | $711.6M | ||
| Q3 25 | $727.2M | $630.1M | ||
| Q2 25 | $757.8M | $608.6M | ||
| Q1 25 | $798.5M | $580.3M | ||
| Q4 24 | $778.3M | $570.1M | ||
| Q3 24 | $749.6M | $554.6M | ||
| Q2 24 | $879.3M | $537.2M |
| Q1 26 | $1.2B | $804.9M | ||
| Q4 25 | $1.3B | $785.8M | ||
| Q3 25 | $1.3B | $710.2M | ||
| Q2 25 | $1.5B | $693.5M | ||
| Q1 25 | $1.6B | $665.0M | ||
| Q4 24 | $1.6B | $641.1M | ||
| Q3 24 | $1.5B | $632.8M | ||
| Q2 24 | $1.6B | $613.2M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
